^
    Back
    Association details:
    Biomarker:MET positive
    Cancer:Non Small Cell Lung Cancer
    Drug:telisotuzumab vedotin (ABBV-399) (Microtubule inhibitor, c-MET-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Lung-MAP S1400K: c-MET Positive

    Excerpt:
    ...Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA)...
    Trial ID:
    LUNG-MAP SUB-STUDY
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma

    Published date:
    08/23/2021
    Excerpt:
    Forty of 52 patients were c-Met+ (33 nonsquamous, six squamous, one mixed histology) and were included in the efficacy-evaluable population. Of those, nine (23%) had objective responses with median duration of response of 8.7 months; median progression-free survival was 5.2 months. Teliso-V monotherapy was tolerated and showed antitumor activity in c-Met+ NSCLC.
    DOI:
    10.1158/1078-0432.CCR-21-0765